Acute Kidney Injury (AKI) is a significant clinical issue affecting nephrologists, intensivists, general physicians, and surgeons. It is associated with adverse short and long-term outcomes, including chronic kidney disease (CKD). The Kidney Disease Improving Global Guidelines (KDIGO) Clinical Practice Guidelines for Acute Kidney Injury provide a comprehensive synthesis of evidence to support AKI management. The guidelines focus on four key domains: AKI definition, prevention and treatment, contrast-induced AKI (CI-AKI), and dialysis interventions. **AKI Definition:** The KDIGO recommends adopting the AKI Network definition, which includes: - An increase in serum creatinine by ≥0.3 mg/dl within 48 hours. - An increase in serum creatinine to ≥1.5 times baseline within the previous 7 days. - Urine volume ≤0.5 ml/kg/h for 6 hours. AKI should be staged according to severity, with higher stages associated with increased risk of death and renal replacement therapy (RRT). **Prevention and Treatment of AKI:** The guidelines make 25 practice statements, emphasizing the use of isotonic crystalloids for volume expansion, insulin therapy to target plasma glucose, and avoiding certain drugs like aminoglycosides. They also recommend using liposomal amphotericin or azoles for fungal and parasitic infections and avoiding N-acetylcysteine (NAC) for postsurgical AKI. **Contrast-Induced Acute Kidney Injury (CI-AKI):** CI-AKI affects about 10.5% of patients and has a mortality rate of up to 35% in those requiring dialysis. The guidelines recommend assessing risk for CI-AKI and screening for kidney disease in patients requiring iodinated contrast. Oral fluid loading is suggested over intravenous fluid loading, and NAC is recommended despite modest effects. **Dialysis Interventions:** The guidelines cover various aspects of dialysis, including initiation and withdrawal of RRT, anticoagulation, and membrane use. Key recommendations include the use of citrate for continuous RRT and the measurement of dialysis dose using Kt/V. However, there is limited evidence to support many of these practices, and the guidelines acknowledge the lack of well-designed interventional studies. **Conclusions:** The KDIGO guidelines provide nuanced guidance based on extensive evidence reviews, emphasizing the need for further research. The use of empirical definitions and staging systems for AKI is controversial, and the guidelines encourage clinicians to use them as a starting point for further inquiries.Acute Kidney Injury (AKI) is a significant clinical issue affecting nephrologists, intensivists, general physicians, and surgeons. It is associated with adverse short and long-term outcomes, including chronic kidney disease (CKD). The Kidney Disease Improving Global Guidelines (KDIGO) Clinical Practice Guidelines for Acute Kidney Injury provide a comprehensive synthesis of evidence to support AKI management. The guidelines focus on four key domains: AKI definition, prevention and treatment, contrast-induced AKI (CI-AKI), and dialysis interventions. **AKI Definition:** The KDIGO recommends adopting the AKI Network definition, which includes: - An increase in serum creatinine by ≥0.3 mg/dl within 48 hours. - An increase in serum creatinine to ≥1.5 times baseline within the previous 7 days. - Urine volume ≤0.5 ml/kg/h for 6 hours. AKI should be staged according to severity, with higher stages associated with increased risk of death and renal replacement therapy (RRT). **Prevention and Treatment of AKI:** The guidelines make 25 practice statements, emphasizing the use of isotonic crystalloids for volume expansion, insulin therapy to target plasma glucose, and avoiding certain drugs like aminoglycosides. They also recommend using liposomal amphotericin or azoles for fungal and parasitic infections and avoiding N-acetylcysteine (NAC) for postsurgical AKI. **Contrast-Induced Acute Kidney Injury (CI-AKI):** CI-AKI affects about 10.5% of patients and has a mortality rate of up to 35% in those requiring dialysis. The guidelines recommend assessing risk for CI-AKI and screening for kidney disease in patients requiring iodinated contrast. Oral fluid loading is suggested over intravenous fluid loading, and NAC is recommended despite modest effects. **Dialysis Interventions:** The guidelines cover various aspects of dialysis, including initiation and withdrawal of RRT, anticoagulation, and membrane use. Key recommendations include the use of citrate for continuous RRT and the measurement of dialysis dose using Kt/V. However, there is limited evidence to support many of these practices, and the guidelines acknowledge the lack of well-designed interventional studies. **Conclusions:** The KDIGO guidelines provide nuanced guidance based on extensive evidence reviews, emphasizing the need for further research. The use of empirical definitions and staging systems for AKI is controversial, and the guidelines encourage clinicians to use them as a starting point for further inquiries.